Background: Reports of pulmonary edema complicating inhaled nitric oxide therapy in patients with chronic heart failure and pulmonary hypertension have raised the concern that inhaled nitric oxide may have negative inotropic effects. 
unaltered. This selectivity is a result of the rapid sequestration and inactivation of NO by hemoglobin before NO reaches the systemic circulation. 34 However, reports of significant increases in pulmonary artery wedge pressure in patients with heart failure receiving inhaled NO therapy 6 have raised important questions about this therapy. Emerging evidence that endogenous NO exerts negative inotropic effects 7-9 has led some investigators to wonder whether the increase in pulmonary artery wedge pressure is a result of negative inotropic actions of inhaled NO therapy, t°' 11 Because of the potential of inhaled NO to counteract the pulmonary vasoconstrictive effects of cardiopulmonary bypass, 12' 13 and to evaluate the reversibility of pulmonary hypertension in cardiac transplant candidates, an understanding of the mechanisms by which inhaled NO causes elevations in pulmonary artery wedge pressure in patients with heart failure is clinically important.
The Journal of Thoracic and Cardiovascular Surgery September 1997 We designed this study to determine whether inhaled NO alters the ventricular contractile state. To this purpose, we studied the effect of inhaled NO in a porcine model of pulmonary hypertension in which state-of-the-art measurements of left ventricular (LV) function were collected at various concentrations of inhaled NO.
Methods
Animals received humane care in compliance with the "Principles of Laboratory Animal Care" formulated by the Institute of Laboratory Animal Resources and the "Guide for the Care and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 86-23, revised 1985) . In addition, this study also conforms with the position of the American Heart Association on Research Animal Use.
Experimental preparation. The protocol was carried out in conditioned Yorkshire pigs weighing 45 to 50 kg. Animals were anesthetized with acepromazine (0.5 mgA:g intramuscularly), ketamine (20 mg/kg intramuscularly), and atropine (1 to 2 mg intramuscularly). The lungs were mechanically ventilated, and ventilatory parameters were adjusted to maintain normocarbia as evidenced by frequent blood gas analyses. Normothermia was maintained by the use of two warming blankets and a heating lamp when necessary. Anesthesia was maintained with isoflurune (1.5% to 2.0%) in 30% oxygen. The femoral artery was catheterized to monitor systemic blood pressure (mean arterial pressure) and to obtain samples for blood gas analysis. Through a midline sternotomy and longitudinal pericardiotomy, the inferior vena cava, pulmonary artery (PA), and ascending aorta were isolated with snares. Three 5F micromanometer-tipped catheters (Millar Instruments, Inc., Houston, Tex.) were placed in the left atrium, right atrium, and PA through purse-string sutures in the atrial appendages and PA for continuous pressure monitoring. A 16 mm perivascular flow probe (Transonic System, Inc., Ithaca, N.Y.) was placed around the main PA. This flow probe was connected to an ultrasonic flowmeter that had a continuous display of cardiac output. A 5F Miltar micromanometer was placed in the right external carotid artery and advanced into the ascending aorta to monitor aortic pressure. A twelveelectrode (1.0 cm interelectrode spacing) 6F micromanometer-tipped conductance catheter (Sentron, Federal Way, Wash.) was inserted through the left common carotid artery, advanced over the aortic valve into the LV, and positioned in the apex to measure LV volume and pressure. This catheter was connected to a signal conditioner (Leycom 5, Cardiodynamics, The Hague, The Netherlands), which provides the conductance signal used for assessing LV volume. This device also measures blood resistivity (0), which is necessary for estimation of volume.
Blood resistivity was measured in each animal before the start of the experimental protocol and after changes in experimental conditions. Proper positioning of the conductance catheter was ensured by palpating the tip in the LV apex and using only segmental volume signals that corresponded to segments residing in the ventricular chamber for generation of the total volume signal. The total conductance signal is affected not only by the conductivity of the blood in the chamber in which the catheter lies, but also by conductive structures that surround the chamber. The contribution to the total conductance signal from these surrounding structures is termed parallel conductance. We determined parallel conductance by the hypertonic saline technique using 5 ml of 5% saline solution rapidly injected into the PA. TM Parallel conductance was recalculated after any change in experimental conditions (i.e., induction of pulmonary hypertension, administration of different concentrations of NO) and before each measurement.
NO administration. After endotracheal intubation, animals received a mixture of oxygen and nitrogen to achieve an inspired fraction of oxygen of 32% to 35%. NO gas (800 ppm in nitrogen) (Alrco; BOC Gases, Murray Hill, N.J.) was delivered at concentrations of 20, 40, and 80 ppm by titrating the amount of nitrogen downward and the level of NO upward so as to maintain a constant inspired oxygen fraction and total gas flow rate of 5 L/rain. The inspired concentration of NO was measured by an NO analyzer (Drager, Chantilly, Va.). Exhaled gases were scavenged and discarded to the atmosphere.
Study protocol. In the first part of the protocol, animals were studied in four conditions: baseline condition and during three different doses (20, 40 , and 80 ppm) of inhaled NO. Next, pulmonary hypertension was induced by continuous intravenous administration of a thromboxane A 2 analog (9,11-dideoxy-lla,9a-epoxymethanoprostaglandin F2; Sigma Chemical Co., St. Louis, Mo.) at a rate that resulted in a mean PA pressure of greater than 35 mm Hg (0.07 to 0.15/zg/kg per minute). Animals were then restudied at the same four conditions just described. Data collected at each condition consisted of standard hemodynamic measurements as well as a series of LV pressure-volume loops measured before and during vena caval occlusion. The vena caval occlusion was limited to 10 seconds in duration to avoid reflex responses and was repeated if arrhythmias occurred. Ventilation was held during the period of data collection. Measurements were made 5 minutes after reaching a steady state NO concentration.
Data analysis. All analog signals were digitized at 200 Hz with the use of a 12-bit analog-to-digital board (ADInstruments, Milford, Mass.) and stored on a removable hard drive for subsequent analysis with IGOR analysis software (Wavemetrics Inc., Lake Oswego, Ore.). Pressures, flow, and volume data were subjected to a five-pass binomial smooth filter. End-diastolic pressure (EDP) was identified as the point just preceding the upstroke of the LV pressure wave. End-diastolic volume (EDV) was determined by the lower right hand corner of the pressure-volume loop. 15 Two relations that describe ventricular contractile state were examined during vena caval occlusion; at least 7 cardiac cycles free of arrhythmias were used for each analysis:
End-systolic pressure-volume relationship (ESPVR).
The slope and volume axis intercept of the end-systolic pressure-volume relationship (ESPVR) were determined as in (SWEDV) . Stroke work was determined for each cardiac cycle by calculating the area within the respective pressure-volume loop. Stroke work-end-diastolic volume (SWEDV) was defined by the relationship between stroke work and end-diastolic volume. 16 Cardiac output was determined by the integral of the PA flow waveform, and pulmonary and systemic vascular resistances were calculated by means of standard formulas.
Statistical analysis. Statistical analyses were performed with InStat software package for Macintosh on an Apple computer (Apple Computer, Cupertino, Calif.). Each relation (ESPVR, SWEDV) was described by a slope and a volume axis intercept obtained from linear regression analysis. The effect of NO on these two variables was assessed by analysis of variance. The impact of NO dose on standard hemodynamic parameters was also assessed by analysis of variance for repeated measures. The Bonferroni correction was applied to account for the fact that comparisons were made between multiple groups. A two-tailed p value < 0.05 was considered statistically significant.
Results
Hemodynamic data measured at baseline and at each NO dose (n --10) before the induction of pulmonary hypertension are presented in Table I . (Table I and Fig. 1, right panel) .
Administration of thromboxane A2 analog resulted in an unstable preparation resulting from arrhythmias, severe systemic hypotension (mean arterial pressure < 40 mm Hg), or death in four animals; these animals were excluded from further study. In the remaining six animals, administration of thromboxane resulted in an elevation (mean _+ standard error of the mean) of baseline pulmonary vascular resistance from 2. 
Discussion
The results of this study demonstrate that inhaled NO does not lead to alterations in LV contractile state. In fact, the only observed hemodynamic alterations associated with inhaled NO were reductions in PA pressure and pulmonary vascular resistance and a mild elevation in LVEDV. These findings are consistent with other reports of the hemodynamic effects of inhaled NO and further clarify the mechanism by which elevations in pulmonary capillary wedge pressure occur during this therapy.
Inhaled NO is currently an important therapy in a number of clinical situations for both diagnostic and therapeutic purposes. Inhaled NO is being used to test vasoreactivity in patients with heart failure during evaluation for cardiac transplantationl:; fixed pulmonary hypertension is considered a contraindication for transplantation because of the prevalence of perioperative right heart failure 18 ' 19 Inhaled NO is also being used with increasing frequency in the perioperative management of right heart failure in patients undergoing heart transplantation or LV assist device implantation, e° Several :reports of acute elevation in pulmonary artery wedge pressure in the heart failure populations have been published, 6' 10, 11 and concern has emerged that the increase in LV filling pressure reflects negative inotropic actions of this therapy. This concern has been bolstered by laboratory reports of negative inotropic actions of NO in isolated myocyte preparations. 7-9 However, NO is rapidly sequestered by hemoglobin in the blood and thereby should be inactivated long before reaching the systemic circulation, el This rapid sequestration is supported by the lack of systemic vasodilatory effects in the setting of significant pulmonary vasodilation. It is therefore unlikely that when administered via the inhaled route, NO could exert any direct myocardial effects, ee'e3 In fact, results of the present study failed to show any effects of inhaled NO on LV contractile function.
The mechanism by which inhaled NO leads to elevations in LV filling pressure remains to be answered. We observed an increase in LVEDV in response to pulmonary vasodilation and showed that this increase is not due to alterations in ventricular function. This finding is consistent with a recent theoretic analysis of the direct impact of pulmonary vasodilation on pulmonary venous pressure. 24 In this study, Dickstein and Burkhoff 24 showed that progressive pulmonary vasodilation is associated with increases in pulmonary wedge pressure independent of changes in ventricular function. Importantly, it was also shown that the magnitude of increase in pulmonary wedge pressure was most affected by intravascular volume. The present study was conducted under euvolemic conditions, and we still observed increases in LVEDV. Operating on the flat portion of the normal diastolic compliance curve, it is not surprising that we observed no significant increase in LVEDP. It is likely that with larger intravascular volumes and/or operating on the steeper portion of a diastolic compliance curve, the increases in LVEDP relative to LVEDV would be more profound.
In summary, we have demonstrated that inhaled NO therapy does not affect the inotropic state of the normal myocardium. Under conditions of pulmonary hypertension and an intact LV, inhaled NO therapy produces selective pulmonary vasodilation and does not affect myocardial contractile performance. The rise in left atrial pressure in patients with preexisting LV dysfunction receiving inhaled NO therapy appears to be a direct consequence of pulmonary vasodilation.
